









Markets
/
Stocks
/
nasdaq-immp
/

Immutep Ltd

IMMP

1.770USD

+0.030+1.72%

Market hours （ET）Quotes delayed by 15 min

2.58BMarket Cap

--P/E TTM



Immutep Ltd

1.770

+0.030+1.72%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Immutep Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Immutep Ltd's Score

Industry at a Glance

Industry Ranking

282 / 501

Overall Ranking

515 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

8.263

Target Price

+388.96%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Immutep Ltd Highlights

StrengthsRisks

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Growing

The company is in a growing phase, with the latest annual income totaling USD 92.04K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 92.04K.

Fairly Valued

The company’s latest PE is -31.81, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.80M shares, decreasing 20.90% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92. Its latest quarterly revenue reached 36.67K, representing a year-over-year decrease of 73.01%, while its net profit experienced a year-over-year decrease of 9.38%.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Immutep Ltd's Company Valuation

Currency: USD Updated: 2025-10-27

There is no valuation score for this company; the Biotechnology & Medical Research industry's average is 6.98. Its current P/E ratio is -31.81, which is -21.57% below the recent high of -24.95 and -319.49% above the recent low of -133.43.

Score

Industry at a Glance

Previous score

0.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 282/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 9.00, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Immutep Ltd is 8.26, with a high of 12.00 and a low of 4.53.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

8.263

Target Price

+374.91%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Immutep Ltd

IMMP

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 7.41, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 2.30 and the support level at 1.77, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.44

Change

-0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.086

Sell

RSI(14)

38.901

Neutral

STOCH(KDJ)(9,3,3)

13.883

Neutral

ATR(14)

0.092

Low Volatility

CCI(14)

-84.851

Neutral

Williams %R

79.545

Sell

TRIX(12,20)

-0.286

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.716

Buy

MA10

1.818

Sell

MA20

1.938

Sell

MA50

1.831

Sell

MA100

1.762

Buy

MA200

1.792

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Pengana Capital Group Limited

970.61K

BlackRock Institutional Trust Company, N.A.

599.94K

-7.46%

Meridian Wealth Management, LLC

372.70K

-3.61%

AllianceBernstein L.P.

140.05K

+79.25%

Sender Company & Partners, Inc

122.75K

Morgan Stanley & Co. LLC

112.97K

+1088.99%

UBS Financial Services, Inc.

64.84K

+170.08%

Steward Partners Investment Advisory, LLC

61.00K

Susquehanna International Group, LLP

58.31K

+22.87%

Dimensional Fund Advisors, L.P.

45.17K

-0.71%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 1.88. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.